Konstantin H Dragnev
Overview
Explore the profile of Konstantin H Dragnev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1967
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wood C, Lyniv L, Isaacs J, Kaufman J, Oduah E, Clarke J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904561
Background: Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. Methods: This is a single-arm phase II study of perioperative pembrolizumab...
2.
Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, et al.
J Thorac Oncol
. 2024 Aug;
19(12):1618-1629.
PMID: 39111731
Introduction: Squamous cell cancer (SqCC) is a lung cancer subtype with few targeted therapy options. Molecular characterization, that is, by next-generation sequencing (NGS), is needed to identify potential targets. Lung...
3.
Bouley S, Grassetti A, Allaway R, Wood M, Hou H, Burdon Dasbach I, et al.
J Cell Sci
. 2024 Jul;
137(15).
PMID: 39016685
Neurofibromatosis type 1, a genetic disorder caused by pathogenic germline variations in NF1, predisposes individuals to the development of tumors, including cutaneous and plexiform neurofibromas (CNs and PNs), optic gliomas,...
4.
Yendamuri S, Dragnev K
Cancer Prev Res (Phila)
. 2024 Jun;
17(9):399-400.
PMID: 38884213
In this secondary analysis of specimens from the CANTOS trial, the investigators find that patients with clonal hematopoiesis mutations, particularly in the TET2 gene, predict a benefit of decreased cancer...
5.
Sankar K, Redman M, Dragnev K, Henick B, Iams W, Blanke C, et al.
Am Soc Clin Oncol Educ Book
. 2024 May;
44(3):e100040.
PMID: 38771997
Clinical trials are essential for advancing oncology treatment strategies and have contributed significantly to the decline in cancer mortality rates over the past decades. Traditional explanatory trials, focused on establishing...
6.
Riano I, Dragnev K, Phillips J
Transl Lung Cancer Res
. 2023 Dec;
12(11):2359-2365.
PMID: 38090512
No abstract available.
7.
Vaidya R, Unger J, Qian L, Minichiello K, Herbst R, Gandara D, et al.
JCO Precis Oncol
. 2023 Sep;
7:e2300218.
PMID: 37677122
Purpose: Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established infrastructure for conducting a biomarker-driven master protocol in molecularly targeted therapies. We compared characteristics of patients enrolled in Lung-MAP with...
8.
Dragnev K, Lubet R, Miller M, Sei S, Fox J, You M
Cancer Prev Res (Phila)
. 2023 Jul;
16(10):549-560.
PMID: 37468135
Therapeutic targeting of RAS-mutated cancers is difficult, whereas prevention or interception (treatment before or in the presence of preinvasive lesions) preclinically has proven easier. In the A/J mouse lung model,...
9.
Riano I, Abuali I, Sharma A, Durant J, Dragnev K
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259381
The neoadjuvant use of immune checkpoint inhibitors (ICI) in resectable non-small cell lung cancer (NSCLC) is being increasingly adopted, but questions about the most appropriate applications remain. Although patients with...
10.
Gadgeel S, Miao J, Riess J, Moon J, Mack P, Gerstner G, et al.
Clin Cancer Res
. 2023 May;
29(18):3641-3649.
PMID: 37233987
Purpose: Efficacy of MEK inhibitors in KRAS+ NSCLC may differ based on specific KRAS mutations and comutations. Our hypothesis was that docetaxel and trametinib would improve activity in KRAS+ NSCLC...